University of Alabama at Birmingham
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Alabama at Birmingham sits in the top decile of US sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count).
University of Alabama at Birmingham: 1,160 sponsored US clinical trials, 216 recruiting.
University of Alabama at Birmingham sponsors 1,160 registered US clinical trials on ClinicalTrials.gov, 216 of them currently recruiting, and 723 completed. 97 of these trials are in Phase 3-4 (later-stage) and 259 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.
Top-decile sponsor footprint
University of Alabama at Birmingham ranks in the top decile of sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
723 of 812 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,160 total, page 10 of 24
Intervention Mapping to Adapt a Mindfulness-based Intervention for Adults With Diabetes and Emotional Distress
NCT03987841
Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)
NCT04907032
Improving Age-Related Cognitive Decline With Exercise in Hypertensive Older Adults
NCT05043454
Evaluation of the Lakeshore Online Fitness Program
NCT05138809
Postpartum Glycemia in Women At Risk for Persistent Hyperglycemia
NCT04521712
Effectiveness of Tele-rheumatology for Delivering High Quality Rheumatology Care During the COVID-19 Crisis (EVOLVE)
NCT04704544
Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations
NCT05000502
CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients
NCT03944902
Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)
NCT04692155
Digital Device Users Who Are Treated With Systane Hydration PF
NCT04837807
CPAP Or Nasal Cannula Oxygen for Preterm Infants: A Randomized Controlled Trial
NCT04792099
Effect of Manual Wheelchair Propulsion Workload on Speed, Energy Expenditure, and Propulsion Mechanics
NCT04987177
Virtual Health Focused Acceptance-Based Program for Parents and Youth
NCT04634045
Identifying Perceived Barriers and Facilitators Toward a Liver Transplantation Prehabilitation
NCT04854564
Exercise for Memory Rehabilitation in Epilepsy
NCT04959019
Guided Eight-week Online Acceptance and Commitment Therapy for Distressed Family Caregivers of People With Dementia
NCT04847986
Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction
NCT04340180
Increasing Naloxone Access for Persons Who Use Opioids
NCT04303000
Effects of Different Types of Augmented Feedback on Intrinsic Motivation and Spatiotemporal Gait Performance After Stroke
NCT04740060
Clinical Effort Against Smoke Exposure in Cystic Fibrosis
NCT04777344
Valacyclovir in Neonatal Herpes Simplex Virus Disease
NCT04448392
Community Health Through Engagement and Environmental Renewal
NCT04362475
Development of an Adaptive Treatment for Weight Loss in People With Prediabetes
NCT04745572
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
NCT04380610
A Guided Online ACT Intervention Combined With Psychoeducation for People With Spinal Cord Injury
NCT04670406
Developing an Adaptive Lifestyle Intervention Program in Family Medicine Clinics
NCT04392284
Weight Loss in Adults Over 50 with Obesity
NCT04014296
Tele-monitoring of Post Join Arthroplasty Outcomes: A Feasibility Study
NCT04586296
COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)
NCT04818853
Use of Automated Office Blood Pressure Monitoring
NCT05395403
Reducing Chronic Disease Health Disparities in the Deep South
NCT04297826
Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced Prostate Cancer
NCT04298983
Maximizing the Initial Experience of a Neophyte Scleral Lens Wearer
NCT04583579
Smoking Reduction In Gravid Substance Use Disorders
NCT04132232
Immune Profiles in CF Fungal Infection
NCT04476758
RFN-Advanced Retrograde Femoral Nailing System
NCT05668117
Spinal Cord Injury Program in Exercise
NCT03925077
Trial Comparing Impact of PENG Block on Quality of Recovery Compared to No-block for Primary Total Hip Arthroplasty
NCT04591353
Effects of Reparel™ Knee Sleeve on Knee Osteoarthritis
NCT04743921
High Intensity Interval Exercise SCI
NCT04940598
COVID-19 Study of Safety and Tolerability of Alvelestat
NCT04539795
Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers
NCT04251819
Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer
NCT04091022
A Handwriting Intervention Program for Children With Tic Disorders
NCT04246112
Improving Thinking in Everyday Life After Covid-19
NCT04644172
Preventing Diabetes in the Deep South: Extending Partnerships and Adapting Interventions to Reach Rural Communities at High Risk.
NCT04343872
Assessing Neuroinflammation in GWI Using MRS
NCT04638998
Feasibility of a New Model for Exercise Prescription in Cystic Fibrosis
NCT04075864
Reducing Adverse Delivery Outcomes Through Teleneonatology: A Feasibility Study
NCT04258722
The Effect of Guanfacine on Delirium in Critically Ill Patients
NCT04578886
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 129 |
| Phase 2 | 130 |
| Phase 3 | 25 |
| Phase 4 | 72 |
Therapeutic Areas
What is open in the University of Alabama at Birmingham pipeline
216 recruiting of 1,160 indexed (19% open); 723 completed (62%).
Phase mix: 97 late (III/IV) vs 259 early (I/II) (early-phase heavy).
Top condition: Obesity (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Alabama at Birmingham: open-pipeline peers nationwide
Peers matched on 1,160 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,160 trials (± recruiting share)
- NYU Langone Health · 1,164 trials · 17% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 19% open enrollment (± trial volume)
- University of Minnesota · 19% recruiting · 966 trials
- Mclean Hospital · 19% recruiting · 140 trials
- Children's Hospital Medical Center, Cincinnati · 19% recruiting · 571 trials
- Arkansas Children's Hospital Research Institute · 19% recruiting · 97 trials
Related
What to do with this University of Alabama at Birmingham page
1,160 registered trials is a research-attention snapshot, not an endorsement of University of Alabama at Birmingham or any single study.
- 216 of University of Alabama at Birmingham's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition University of Alabama at Birmingham studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Alabama at Birmingham pipeline card: 1,160 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.